Table 5. Hazard ratios of clinical characteristics associated with overall mortality in patients with portal vein invasion with or without distant metastasis.

Univariate model	HR (95% CI)	P value
Age, per 1 year	0.99 (0.97-1.01)	0.23
Sex, male	0.87 (0.50-1.50)	0.61
Etiology		0.92
Hepatitis B virus	1.15 (0.42-3.17)	0.79
Hepatitis C virus	1.21 (0.30-4.96)	0.79
Others or unknown	1.21 (0.66-2.22)	0.54
Child-Pugh stage, B	1.59 (1.07-2.37)	0.021
AFP ≥ 400 ng/mL	1.19 (0.80-1.78)	0.39
ECOG performance status, 1	1.87 (1.27-2.76)	0.001
Duration of sorafenib treatment, per 1 week	0.97 (0.95-0.98)	<0.001
TACE procedure during the study period	0.47 (0.30-0.72)	0.001
Radiation therapy for portal vein invasion	0.71 (0.48-1.04)	0.08
Presence of distant metastasis	1.01 (0.69-1.47)	0.97
Multivariate model	OR (95% CI)	P value
Child-Pugh stage, B	1.83 (1.20-2.79)	0.005
ECOG performance status, 1	1.37 (0.92-2.04)	0.12
Duration of sorafenib treatment, per 1 week	0.96 (0.94-0.98)	<0.001
TACE procedure during the study period	0.24 (0.15-0.41)	<0.001
Radiation therapy for portal vein invasion	0.79 (0.51-1.25)	0.32

HR, hazard ratio; CI, confidence interval; AFP, alpha fetoprotein; ECOG, Eastern Cooperative Oncology Group; TACE, transarterial chemoembolization